Beyond Time Is Brain: The Time,Tissue,and Systems Framework for Acute Stroke

Abstract

Acute ischaemic stroke care has long been guided by the maxim “time is brain,” yet outcome variability suggests that clock time alone is insufficient. We propose the Time, Tissue, and Systems (TTS) framework, a quantitative model integrating temporal progression, tissue vulnerability, and health-system performance. Biological injury is conceptualized as accelerated neuronal loss scaled by tissue phenotype and systems friction, and clinical decision-making is reframed as net utility optimization. Illustrative modeling across four archetypal stroke profiles demonstrates how identical clock times yield divergent biological and functional trajectories. The TTS framework provides a coherent structure for precision stroke care, aligning biological time with system time.

Keywords

acute ischaemic stroke framework biological time reperfusion therapy clinical utility modeling

Reframing the Urgency of Stroke

Stroke has long been described as a “brain attack,” a term deliberately chosen to convey urgency and elevate acute ischaemic stroke (AIS) to the same emergency status as myocardial infarction.¹ Quantitative analyses lent this message biological precision: without reperfusion, an estimated 4 million neurons, 12 million brain cells, and 15 billion synapses are lost each minute.² The doctrine “time is brain” reshaped practice, driving thrombolysis, mechanical thrombectomy, stroke units, and regionalised systems of care.^2-5 Yet three decades into the reperfusion era, clinical trajectories remain stubbornly heterogeneous. Patients treated within recommended windows may deteriorate unexpectedly.^6-10 Others presenting beyond conventional thresholds recover when imaging demonstrates viable tissue.^11-14 Posterior circulation strokes show heterogeneous trajectories.^15-19 Transfer delays alter prognosis even when tissue phenotype appears similar.^17,20-24 Mild strokes subjected to reperfusion reveal nuanced risk–benefit balances, incurring substantial haemorrhagic risk without measurable functional benefit.²⁵ These realities suggest that clock time alone does not determine outcome. Stroke unfolds within a dynamic interaction of temporal evolution, tissue vulnerability, and systems performance.^2,14,26 Understanding and quantifying this interaction is essential for the next phase of precision stroke care.

Why Time Alone Is Insufficient

Early thrombolysis and thrombectomy trials established that earlier reperfusion improves outcomes, but subsequent work revealed that therapeutic windows are biologically modulated probabilities rather than fixed constants.^2,4,5,14,27 Collateral circulation, infarct core size, occlusion site, metabolic state, and inflammatory response influence the rate at which irreversible injury accrues.^28-35 Simultaneously, stroke-unit organization, coordinated stroke teams, imaging workflows, and interhospital transfer times independently shape prognosis.^24,36

The expansion of thrombectomy up to 24 hours in selected patients further demonstrated that tissue phenotype can override rigid clock boundaries.^11,14,27 Conversely, systems friction - particularly in transfer pathways - may negate biological advantage despite theoretically favorable imaging.^37-40 These observations underscore a fundamental limitation of single-axis thinking: neither time, tissue, nor systems alone explains outcome heterogeneity. Rather, their interaction determines biological and clinical trajectories. A more complete expression of acute stroke biology may therefore be written simply:

Outcome = f (Time \times Tissue \times Systems) .

This formulation reframes acute stroke not as a race against the clock alone, but as a dynamic interaction between temporal progression, biological substrate, and systemic response.

The Time, Tissue, and Systems Framework

We therefore propose a unifying construct: the Time, Tissue, and Systems (TTS) framework. The probability of favorable functional outcome may be represented as: $P (G) = σ (α + β_{T} Φ_{T} (t) + β_{T i} Φ_{T i} (x) + β_{S} Φ_{S} (z) + β_{int} Φ_{T} (t) Φ_{S} (z))$ where $t$ denotes onset-to-reperfusion time, $x$ reflects tissue phenotype (core volume, collateral grade, metabolic resilience), and $z$ represents systems performance (prehospital delay, door-to-needle time, transfer friction). The interaction term $Φ_{T} (t) Φ_{S} (z)$ formalizes a critical insight: systems performance modifies the biological meaning of time. Clinical decision-making may then be reframed as optimization of net utility:

U = w_{G} P (G) - w_{H} P (H)

Rather than asking whether a patient falls within a time window, this framework asks whether intervention maximizes expected biological and functional benefit.

From Clock Time to Biological Time

The heuristic estimate of 4 million neurons lost per minute without reperfusion provides a biological starting point.² Cumulative neuronal loss may be approximated as:

N_{neur} (t) = 4 \times 10^{6} t

However, neuronal loss is not uniform across patients. Collateral collapse, proximal occlusion, metabolic dysregulation, and delayed systems response accelerate injury.^{24,28-32,37,38} We therefore introduce a biological acceleration factor:

N_{neur} (t) = 4 \times 10^{6} κ (x, z) t

with

κ (x, z) = \exp (η_{0} + η_{x} x + η_{z} z)

Clock time thus becomes biological time, scaled by tissue vulnerability and systems friction. Identical elapsed minutes may correspond to profoundly different biological injury burdens. This conceptual shift is illustrated in Figure 1, where divergent neuronal loss trajectories translate into differential clinical utility across representative stroke archetypes (see Figure 1). Time remains critical, but its biological cost is context-dependent.

Figure 1.

The time, tissue, and systems framework: Biological time and clinical utility in acute stroke.

The contributions in this Special Issue exemplify each axis of the TTS model. Korol and colleagues demonstrate that stroke-related changes in tonic and phasic muscle recruitment during reaching reveal pathway-specific motor deficits, underscoring that tissue injury manifests as network-level reorganization rather than simple lesion volume.⁴¹ Wei and colleagues integrate the triglyceride–glucose index into nomogram models predicting early neurological deterioration and 90-day outcomes in AIS patients undergoing intravenous thrombolysis, providing evidence that systemic metabolic vulnerability modifies tissue resilience.⁴² Rajeswaran and colleagues, in a meta-analysis of mild stroke patients undergoing reperfusion therapy, show heterogeneous outcomes and propose SAFE recommendations, highlighting the narrow decision boundary in distal occlusions.²⁵ Lou’s editorial called for decoding the complexity of stroke treatment and care beyond procedural speed, emphasizing the need for conceptual integration.⁴³ These studies reinforce that outcome variability reflects multidimensional interaction rather than isolated factors.

Archetypes of Interaction

To synthesize the framework, Figure 1 models four archetypal profiles: basilar large-vessel occlusion treated via mothership pathway; basilar occlusion treated via transfer pathway; borderline M2/M3 occlusion managed with endovascular therapy; and wake-up stroke with imaging mismatch. Illustrative model specifications and parameter values used to generate Figure 1 are summarized in Table 1. Divergent biological-time slopes reflect differences in tissue vulnerability and systems friction. These biological trajectories, when translated into net utility, reveal earlier loss of benefit in high-friction systems and prolonged benefit in favorable tissue states. Borderline distal occlusions occupy a narrow intermediate zone, illustrating the probabilistic nature of modern stroke decision-making. These archetypes demonstrate that the relationship between minutes elapsed and neurons lost is neither linear nor universal. Systems engineering, imaging selection, and metabolic profiling become biological interventions.

Table 1.

Illustrative Parameters Used in the Time, Tissue, and Systems (TTS) Model

Component	Model expression	Parameter(s)	Value(s)	Description
Biological Time (Neuronal Loss)	$N_{neur} (t) = 4 \times 10^{6} κ (x, z) t$	Baseline loss rate	4 × 10⁶ neurons/min	Estimated untreated neuronal loss per minute
		$κ (x, z) = \exp (η_{0} + η_{x} x + η_{z} z)$	η₀ = 0.0	Intercept
			η_x = 0.9	Tissue vulnerability weight
			η_z = 1.2	Systems friction weight
Probability of Good Outcome	$P (G) = σ (α + β_{T} t + β_{T i} x + β_{S} z + β_{int} t z)$	α	2.0	Baseline log-odds
		β_T	−0.17	Time effect
		β_{Ti}	−1.40	Tissue effect
		β_S	−1.05	Systems effect
		β_{int}	−0.42	Time × Systems interaction
Probability of Harm	$P (H) = σ (γ + δ_{T} t + δ_{T i} x + δ_{S} z)$	γ	−3.2	Baseline log-odds
		δ_T	0.10	Time-related harm
		δ_{Ti}	1.05	Tissue-related harm
		δ_S	1.15	Systems-related harm
Net Utility	$U = w_{G} P (G) - w_{H} P (H)$	w_G	1.0	Weight for benefit
Net Utility		w_H	0.85	Weight for harm
Case-Specific Inputs		A (Basilar LVO – Mothership)	x=0.45, z=0.25	κ≈2.04
		B (Basilar LVO – Transfer)	x=0.45, z=0.70	κ≈3.48
		C (Borderline M2/M3 – EVT)	x=0.28, z=0.30	κ≈1.86
		D (Wake-up – Mismatch)	x=0.22, z=0.25	κ≈1.65

All parameters are illustrative and were selected for conceptual demonstration of the Time, Tissue, and Systems framework. Values are not calibrated to patient-level clinical datasets.

Conclusion

Stroke is not merely a race against the clock. It is a dynamic interaction between temporal progression, tissue vulnerability, and systemic response. While the maxim “time is brain” remains foundational, it is no longer sufficient to explain clinical variability.^2,14,27 Biological time progresses at different rates across patients and pathways, and systems performance determines whether that progression is mitigated or amplified.^20,38,44,45 The TTS framework offers a coherent, quantitative model for integrating these dimensions. By formalizing the principle that Outcome = f(Time × Tissue × Systems), it transforms urgency into measurable strategy.^23,40,46 The next era of acute stroke care will not be defined solely by faster treatment, but by deeper alignment of biological time with system time.^24,47

Footnotes

Acknowledgments

SB gratefully acknowledges financial support from the Japan Society for the Promotion of Science (JSPS) International Fellowship (Grant ID: P23712) and the Grant-in-Aid for Scientific Research (KAKENHI) (Grant ID: 23KF0126).

ORCID iD

Sonu Bhaskar

Ethical Considerations

Institutional review board approval was not required, as this article is an editorial and does not involve human participants, patient data, or identifiable information.

Consent to Participate

Written informed consent was therefore not required.

Author Contributions

SB conceived the Time, Tissue, and Systems (TTS) framework, developed the methodology and formal modeling, performed the analyses, curated and validated the data inputs, generated visualizations and outputs, secured funding and resources, administered and supervised the project, and drafted and critically revised the manuscript.

Funding

The author disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: financial support for a separate project was received through the Grant-in-Aid for Scientific Research (KAKENHI) (PI: S.B.), funded by the Japan Society for the Promotion of Science (JSPS), Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan (Grant ID: 23KF0126). S.B. was awarded the JSPS International Fellowship, supported by MEXT and the Australian Academy of Science, for the period 2023–2025 (Grant ID: P23712).

Declaration of Conflicting Interests

The author declared the following potential conficts of interest with respect to the research, authorship, and/or publication of this article: SB reports leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with the National Cerebral and Cardiovascular Center (Osaka, Japan) as Visiting Director (2023–2025); Rotary District 9675 (Sydney, Australia) as District Chair for Diversity, Equity, and Inclusion; the Global Health and Migration Hub Community, Global Health Hub Germany (Berlin, Germany) as Chair, Founding Member, and Manager; and editorial board memberships at PLOS One, BMC Neurology, Frontiers in Neurology, Frontiers in Stroke, Frontiers in Public Health, Journal of Aging Research, Neurology International, Vas-Cog Japan, TouchNeurology, Diagnostics, and BMC Medical Research Methodology. Additionally, SB serves as a Member of the College of Reviewers for the Canadian Institutes of Health Research (CIHR), Government of Canada; Director of Research for the World Headache Society (Bengaluru, India); a member of the Scientific Review Committee at Cardiff University Biobank (Cardiff, UK); Chair of the Rotary Reconciliation Action Plan (RAP), Rotary District 9675 (NSW, Australia), Scientific Adviser of Japan Connect (Osaka, Japan), and as an Expert Adviser/Reviewer for the Cariplo Foundation (Milan, Italy). These roles are unrelated to the submitted work. The funding body has no role in the study design, data collection, analysis, interpretation of findings, and manuscript preparation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the affiliated/funding organisation/s.

Data Availability Statement

All information supporting this article is contained within the main text. No additional datasets were generated or analyzed. Further inquiries may be directed to the corresponding author.*

References

Hassan

Rohatgi

. Brain Attack: Time to Act Now. Med J Armed Forces India. 2009;65(1):62-65. doi:10.1016/s0377-1237(09)80059-2.

Saver

. Time is brain--quantified. Stroke. 2006;37(1):263-266. doi:10.1161/01.STR.0000196957.55928.ab.

Meretoja

Keshtkaran

Tatlisumak

Donnan

Churilov

. Endovascular therapy for ischemic stroke: Save a minute-save a week. Neurology. 2017;88(22):2123-2127. doi:10.1212/wnl.0000000000003981.

Hacke

Donnan

Fieschi

, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768-774. doi:10.1016/s0140-6736(04)15692-4.

Goyal

Menon

van Zwam

, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723-1731. doi:10.1016/s0140-6736(16)00163-x.

Che

Wang

, et al. Early neurological deterioration in acute ischemic stroke patients after intravenous thrombolysis with alteplase predicts poor 3-month functional prognosis - data from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China). BMC Neurol. 2022;22(1):212. doi:10.1186/s12883-022-02737-8.

Seners

Turc

Oppenheim

Baron

. Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications. J Neurol Neurosurg Psychiatry. 2015;86(1):87-94. doi:10.1136/jnnp-2014-308327.

Simonsen

Schmitz

Madsen

, et al. Early neurological deterioration after thrombolysis: Clinical and imaging predictors. Int J Stroke. 2016;11(7):776-782. doi:10.1177/1747493016650454.

Kobeissi

Ghozy

Seymour

Bilgin

Kadirvel

Kallmes

. Early neurological deterioration as a predictor of outcomes after endovascular thrombectomy for stroke: A systematic review and meta-analysis. Interv Neuroradiol. 2024;30(4):451-457. doi:10.1177/15910199221135289.

10.

Zhu

Zhang

, et al. Risk factors for unexplained early neurological deterioration after intravenous thrombolysis: a meta-analysis. Neurosciences (Riyadh). 2025;30(2):92-100. doi:10.17712/nsj.2025.2.20230105.

11.

Olthuis

SGH

Pirson

FAV

Pinckaers

FME

, et al. Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial. Lancet. 2023;401(10385):1371-1380. doi:10.1016/s0140-6736(23)00575-5.

12.

Morsi

Ghozy

Elfil

, et al. Endovascular thrombectomy for DAWN- and DEFUSE-3 ineligible acute ischemic stroke patients: a systematic review and meta-analysis. J Neurol. 2024;271(5):2230-2237. doi:10.1007/s00415-024-12198-3.

13.

Fujiwara

Uchida

Ohta

, et al. Impact of the mode of onset after endovascular treatment for acute ischemic stroke in the post DAWN and DEFUSE-3 era. J Neurol Sci. 2025;475:123584. doi:10.1016/j.jns.2025.123584.

14.

Albers

Marks

Kemp

, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018;378(8):708-718. doi:10.1056/NEJMoa1713973.

15.

Searls

Pazdera

Korbel

Vysata

Caplan

. Symptoms and signs of posterior circulation ischemia in the new England medical center posterior circulation registry. Arch Neurol. 2012;69(3):346-351. doi:10.1001/archneurol.2011.2083.

16.

Inoa

Aron

Staff

Fortunato

Sansing

. Lower NIH stroke scale scores are required to accurately predict a good prognosis in posterior circulation stroke. Cerebrovasc Dis. 2014;37(4):251-255. doi:10.1159/000358869.

17.

Guo

Xie

Chai

, et al. Clinical outcomes of endovascular treatment for acute basilar artery occlusion patients with extremely severe symptoms. Front Neurol. 2025;16:1736679. doi:10.3389/fneur.2025.1736679.

18.

Yeo

LLL

Chien

Lin

, et al. Derivation and Validation of a Scoring System for Intravenous Tissue Plasminogen Activator Use in Asian Patients. J Stroke Cerebrovasc Dis. 2017;26(8):1695-1703. doi:10.1016/j.jstrokecerebrovasdis.2017.03.033.

19.

Alemseged

Nguyen

Alverne

Liu

Schonewille

Nogueira

. Endovascular Therapy for Basilar Artery Occlusion. Stroke. 2023;54(4):1127-1137. doi:10.1161/strokeaha.122.040807.

20.

Pardo

Naftali

Barnea

, et al. Effect of time delay in inter-hospital transfer on outcomes of endovascular treatment of acute ischemic stroke. Front Neurol. 2023;14:1303061. doi:10.3389/fneur.2023.1303061.

21.

Chaudhry

Jadran

Laleka

, et al. The impact of interhospital transfer on patients undergoing endovascular thrombectomy for acute ischemic stroke from a comprehensive stroke center. Neurol Res. 2025;1-8. doi:10.1080/01616412.2025.2560070.

22.

Holodinsky

Patel

Thornton

, et al. Drip and ship versus direct to endovascular thrombectomy: The impact of treatment times on transport decision-making. Eur Stroke J. 2018;3(2):126-135. doi:10.1177/2396987318759362.

23.

Holodinsky

Williamson

Demchuk

, et al. Modeling Stroke Patient Transport for All Patients With Suspected Large-Vessel Occlusion. JAMA Neurol. 2018;75(12):1477-1486. doi:10.1001/jamaneurol.2018.2424.

24.

Chowdhury

Baskar

Bhaskar

. Effect of prehospital workflow optimization on treatment delays and clinical outcomes in acute ischemic stroke: A systematic review and meta-analysis. Acad Emerg Med. 2021;28(7):781-801. doi:10.1111/acem.14204.

25.

Rajeswaran

Huasen

Stanwell

Killingsworth

Bhaskar

SMM

. Prevalence and outcomes of mild stroke patients undergoing reperfusion therapy: A meta-analysis and SAFE recommendations for optimal management. J Cent Nerv Syst Dis. 2025;17:11795735251314881. doi:10.1177/11795735251314881.

26.

Campbell

BCV

Majoie

Albers

, et al. Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data. Lancet Neurol. 2019;18(1):46-55. doi:10.1016/s1474-4422(18)30314-4.

27.

Nogueira

Jadhav

Haussen

, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018;378(1):11-21. doi:10.1056/NEJMoa1706442.

28.

Marilena

Romana

Guido

, et al. From “time is brain” to “time is collaterals”: updates on the role of cerebral collateral circulation in stroke. J Thromb Thrombolysis. 2025;58(7):821-832. doi:10.1007/s11239-025-03135-w.

29.

Yang

Cavalcante

Treurniet

, et al. Arterial collateral status and treatment effect of intravenous alteplase thrombolysis prior to endovascular treatment in patients with anterior circulation large vessel occlusion: prespecified analysis of the MR CLEAN-NO IV trial. J Neurointerv Surg. 2025;17(10):1051-1058. doi:10.1136/jnis-2025-023054.

30.

van der Hoeven

McVerry

Vos

, et al. Collateral flow predicts outcome after basilar artery occlusion: The posterior circulation collateral score. Int J Stroke. 2016;11(7):768-775. doi:10.1177/1747493016641951.

31.

Gao

Sun

. The non-linear relationship between the metabolic score for insulin resistance and three-month outcomes in the individuals with acute ischemic stroke: a prospective Korean cohort study. BMC Neurology. 2025;25(1):280. doi:10.1186/s12883-025-04299-x.

32.

Sun

Deng

Luo

Chen

. Effect of Insulin Resistance on Prognosis of Intravenous Thrombolysis in Acute Ischemic Stroke Patients with or Without Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2025;18:1299-1309. doi:10.2147/dmso.S513652.

33.

Bradley

Smokovski

Bhaskar

SMM

. Impact of diabetes on clinical and safety outcomes in acute ischemic stroke patients receiving reperfusion therapy: A meta-analysis. Adv Clin Exp Med. 2022;31(6):583-596. doi:10.17219/acem/146273.

34.

Sinha

Gupta

Bhaskar

SMM

. Evolucollateral dynamics in stroke: Evolutionary pathophysiology, remodelling and emerging therapeutic strategies. Eur J Neurosci. 2024;60(11):6779-6798. doi:10.1111/ejn.16585.

35.

Sinha

Stanwell

Killingsworth

Bhaskar

SMM

. Prognostic accuracy and impact of cerebral collateral status on clinical and safety outcomes in acute ischemic stroke patients receiving reperfusion therapy: a systematic meta-analysis. Acta Radiol. 2023;64(2):698-718. doi:10.1177/02841851221080517.

36.

Baskar

Chowdhury

Bhaskar

SMM

. In-hospital systems interventions in acute stroke reperfusion therapy: a meta-analysis. Acta Neurol Scand. 2021;144(4):418-432. doi:10.1111/ane.13476.

37.

Froehler

Saver

Zaidat

, et al. Interhospital Transfer Before Thrombectomy Is Associated With Delayed Treatment and Worse Outcome in the STRATIS Registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke). Circulation. 2017;136(24):2311-2321. doi:10.1161/circulationaha.117.028920.

38.

Katsanos

Poppe

Swartz

, et al. Interhospital Transfer for Endovascular Stroke Treatment in Canada: Results From the OPTIMISE Registry. Stroke. 2024;55(8):2103-2112. doi:10.1161/strokeaha.124.046690.

39.

Patil

Deshmukh

Gagné

, et al. Predictors of Futile Inter-Hospital Transfer for Endovascular Thrombectomy in Anterior Circulation Acute Ischemic Stroke Due to Large Vessel Occlusion. Brain Sciences. 2025;15(12):1320. doi:10.3390/brainsci15121320.

40.

Royan

Stamm

Giurcanu

, et al. Door-in-door-out times and outcomes in patients with acute ischaemic stroke transferred for endovascular therapy in the USA: a retrospective cohort study. The Lancet Neurology. 2026;25(2):160-169. doi:10.1016/S1474-4422(25)00478-8.

41.

Korol

Adcock

Gritsenko

. Stroke-Related Changes in Tonic and Phasic Muscle Recruitment During Reaching Reveal Pathway-Specific Motor Deficits. J Cent Nerv Syst Dis. 2025;17:11795735251394491. doi:10.1177/11795735251394491.

42.

Wei

Zhou

, et al. Nomogram Models Integrating TyG Index for Predicting Early Neurological Deterioration and 90-Day Outcomes in AIS Patients Undergoing IVT. J Cent Nerv Syst Dis. 2025;17:11795735251382435. doi:10.1177/11795735251382435.

43.

Lou

. Unlocking the code for stroke treatment and care. J Cent Nerv Syst Dis. 2024;16:11795735241280805. doi:10.1177/11795735241280805.

44.

Rocha

Jovin

. Fast Versus Slow Progressors of Infarct Growth in Large Vessel Occlusion Stroke: Clinical and Research Implications. Stroke. 2017;48(9):2621-2627. doi:10.1161/strokeaha.117.017673.

45.

Cui

Yang

Zhang

, et al. Machine Learning-Based Model for Predicting Incidence and Severity of Acute Ischemic Stroke in Anterior Circulation Large Vessel Occlusion. Front Neurol. 2021;12:749599. doi:10.3389/fneur.2021.749599.

46.

Iyyangar

Kim

, et al. Machine Learning-Enabled Automated Large Vessel Occlusion Detection Improves Transfer Times at Primary Stroke Centers. Stroke Vasc Interv Neurol. 2024;4(3):e001119. doi:10.1161/svin.123.001119.

47.

Alberts

Ollenschleger

Nouh

. Dawn of a New Era for Stroke Treatment: Implications of the DAWN Study for Acute Stroke Care and Stroke Systems of Care. Circulation. 2018;137(17):1767-1769. doi:10.1161/circulationaha.118.033579.